Nicotinic receptors and schizophrenia

Current Medical Research and Opinion

Volumn 20, Issue 7, 2004, Pages 1057-1074

  Ripoll, Nadège ^a   Bronnec, Marie ^a   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Cognitive; Nicotinic receptors; Schizophrenia; Sensory gating; Smoking; Tobacco

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA BUNGAROTOXIN; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CLOZAPINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTISINE; DONEPEZIL; DOPAMINE; EXCITATORY AMINO ACID RECEPTOR; GALANTAMINE; GLUTAMIC ACID; GLYCINE RECEPTOR; HALOPERIDOL; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORADRENALIN; PHYSOSTIGMINE; RECEPTOR SUBUNIT; RISPERIDONE; SEROTONIN; SEROTONIN 3 RECEPTOR; TACRINE; TRITIUM; UNINDEXED DRUG;

BINDING ASSAY; BRAIN REGION; CADAVER; COGNITIVE DEFECT; DISEASE EXACERBATION; DOPAMINE RELEASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; GENETIC LINKAGE; GENETIC RISK; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LINKAGE ANALYSIS; MENTAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SENSORY DYSFUNCTION; SMOKING; SMOKING CESSATION; SYMPTOM;

COGNITION; HUMANS; INCIDENCE; NEUROTRANSMITTER AGENTS; NICOTINE; POLYMORPHISM, GENETIC; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SENSATION; SMOKING; TOBACCO;

EID: 3242678172     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004060     Document Type: Review

References (303)

1. Kraepelin E. Dementia praecox and paraphrenia (Translated by Barclay RM.) Edinburgh: Churchill Livingstone, 1979
2. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000;47:210-20
3. McGrath JJ, Feron FP, Burne TH, Mackay-Sim A, Eyles DW. The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann Med 2003;35:86-93
4. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002;296:692-5
5. Swerdlow NR, Koob JF. Dopamine, schizophrenia, mania and depression: toward a unified hypothesis of cortico-striatopallido-thalamic function. Behav Brain Sci 1987;10:197
6. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9
7. Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 1992;36:61-89
8. Thorne J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. J Neural Transm 1998;105:85-100
9. Snyder SH. Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 1973;130:61-7
10. Angrist B, Van Kammen DP. CNS stimulants as tools in the study of schizophrenia. TINS 1984;7:388-90
11. Deutch AY. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm Gen Sect 1993;91:197-221
12. Pani L. Clinical implications of dopamine research in schizophrenia. Curr Med Res Opin 2002;18:3-7
13. Andreasen N, Flaum M, Swayze VW 2nd, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 1990;47:615-21
14. Kovelman JA, Scheibel AB. Biological substrates of schizophrenia. Acta Neurol Scand 1986;73:1-32
15. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull 1993;19:431-45
16. Jones P, Murray RM. The genetics of schizophrenia is the genetics of neurodevelopment. Br J Psychiatry 1991;158:615-23
17. Weinberger DR, Lipska BK. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995;16:87-110
18. DeLisi LE. Is schizophrenia a lifetime disorder of brain plasticity, growth and aging? Schizophr Res 1997;23:119-29
19. McDonald C, Murray RM. Early and late environmental risk factors for schizophrenia. Brain Res Rev 2000;31:130-7
20. Murray RM, Jones P, O'Callaghan E. Fetal brain development and later schizophrenia. Ciba Found Symp 1991;156:155-63 (discussion 163-70)
21. King DJ. Psychomotor dysfunction in schizophrenia. In: Steinhauer SR. (Ed), Neuropsychology and Information processing. Amsterdam: Elsevier, 1991:273-301
22. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996b;15:429-36
23. Saccuzzo DP, Michael B. Speed of information-processing and structural limitations by mentally retarded and dual-diagnosed retarded-schizophrenic persons. Am J Ment Defic 1984;89:187-94
24. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001;49:258-67
25. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Rotrosen J, Wolkin A. Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms. Psychiatry Research: Neuroimaging 2002;116:1-23
26. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Vimich DE, Waldo M, Walton K, Freedman R. Smoking and mental illness. Pharmacol Biochem Behav 2001;70:561-70
27. Hugues JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7
28. Poirier MF, Canceil O, Baylé F, Millet B, Bourdel MC, Moatti C, Olié JP, Attar-Levy D. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:529-37
29. De Leon J, Tracy J, McCann E, Mcgrory A, Diaz F. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002;56:55-65
30. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5
31. Goff DC, Henderson DC, Amico E. Cigarette smocking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94
32. Hamera E, Schneider JK, Deviney S. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. J Nerv Ment Dis 1995;183:559-65
33. Dalack GW, Meador-Woodruff JH. Smocking, smocking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 1996;22:133-41
34. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-501
35. Srinivasan TN, Thara R. Smoking in schizophrenia - all is not biological. Schizophr Res 2002;56:67-74
36. Decina P, Carraci G, Sandik R. Cigarettes smoking and neuroleptic-induced Parkinsonism. Biol Psychiatry 1989; 25:792-5
37. Lohr JB, Flynn K. Smoking and schizophrenia. Schizophr Res 1992;8:93-102
38. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998;24:189-202
39. Leonard S, Breese C, Adams C, Benhammou K, Gault J, Stevens K, Lee M, Adler L, Olincy A, Ross R, Freedman R. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur J Pharmacol 2000;393:237-42
40. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 1995;15:1231-44
41. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 1993;16:403-30
42. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995;57:521-46
43. Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNSS synapses. Neuron 1996;16:1077-85
44. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT. Properties of neuronal nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1997;280:1117-36
45. Patrick J, Sequela P, Vernino S, Amador M, Luetje C, Dani JA. Functional diversity of neuronal nicotinic acetylcholine receptors. Prog Brain Res 1993;98:113-20
46. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal acetylcholine receptor. Nature 1991;350:235-8
47. Unwin N. Nicotinic acetylcholine receptor at 9 A resolution. J Mol Biol, 1993;229:1101-1124
48. Unwin N. Projection structure of the nicotinic acetylcholine receptors: distinct conformations of the alpha subunits. J Mol Biol 1996;257:586-96
49. Gotti C, Carbonnelle E, Moretti M, Zwart R, Clementi F. Drugs selective for nicotinic receptor subtypes: a real possibility or a dream? Behav Brain Res 2000;113:183-92
50. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. Alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci U S A 2001;98:3501-6
51. Goldman D, Deneris E, Luyten W, Kochhar A, Patrick J, Heinemann S. Members of a nicotinic acetylcholine receptor gene family are expressed in different regions of the mammalian central nervous system. Cell 1987;48(6):965-73
52. Gault J, Robinson M, Berger R, Drebing C, Logel J, Hopkins J, Moore T, Jacobs S, Meriwether J, Choi MJ, Kim EJ, Walton K, Buiting K, Davis A, Breese C, Freedman R, Leonard S. Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics 1998;52:173-85
53. Weiland S, Bertrand D, Leonard S. Neuronal nicotinic acetylcholine receptors: from the gene to the disease. Behav Brain Res 2000;113:43-56
54. Zoli M. NAChR in development and ageing. In: Clementi F, Fornasari D, Gotti C, editors. Neuronal Nicotinic Receptors, Handbook of Experimental Pharmacology, Vol. 144. Berlin: Springer-Verlag, 2000
55. Jacob MH. Acetylcholine receptor expression in developing chick ciliary ganglion neurons. J Neurosci 1991;11:1701-12
56. Corriveau RA, Berg DK. Coexpression of multiple acetylcholine receptor genes in neurons: quantification of transcripts during development. J Neurosci 1993;13:2662-71
57. Rosenberg MM, Blitzblau RC, Olsen DP, Jacob MH. Regulatory mechanisms that govern nicotinic synapse formation in neurons. J Neurobiol 2002;53:542-55
58. Kasa P. The cholinergic systems in brain and spinal cord. Prog Neurobiol 1986;26:211-72
59. Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. Prog Neurobiol 1991;37:475-524
60. 125I]-alpha-bungarotoxin. J Neurosci, 1985;5:1307-15
61. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J comp Neurol 1989;284:314-35
62. Schoepfer R, Conroy WG, Whiting P, Gore M, Lindstrom J. Brain alpha-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron 1990;5:35-48
63. Wada E, McKinnon D, Heinemann S, Patrick J, Swanson LW. The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (α5) in the rat central nervous system. Brain Res 1990;526:45-53
64. Cimino M, Marini P, Fornasari D, Cattabeni F, Clementi F. Distribution of nicotinic receptors in cynomolgus monkey brain and ganglia: localization of alpha 3 subunit mRNA, alpha-bungarotoxin and nicotine binding sites. Neuroscience 1992;51:77-86
65. Séguéla P, Wadiche J, Miller K, Dani JA, Patrick J. Molecular cloning, functional properties and distribution of rat brain α7: A nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604
66. Charpantier E, Barnéoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport 1998;9:3097-3101
67. Rubboli F, Court JA, Sala C, Morris C, Perry E, Clementi F. Distribution of neuronal nicotinic receptor subunits in human brain. Neurochem Int. 1994a;25:69-71
68. Rubboli F, Court JA, Sala C, Morris C, Chini B, Perry E, Clementi F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur J Neurosci, 1994b;6:1596-604
69. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997;53:199-237
70. Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanatomy 2001;22:115-26
71. Pidoplichko V, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997;390:401-4
72. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, Perry RH, Perry EK. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000;98:79-87
73. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to Parkinsonism. Brain Research, 1998;791:186-90
74. 125I]-alpha- bungarotoxin binding in human postmortem brain. J Comp Neurol 1997b;387:385-98
75. Court J, Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis Assoc Disord 1995;9:6-14
76. Dani JA, Radcliffe KA, Pidoplichko V. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas. Eur J Pharmacol 2000;393:31-8
77. Alkondon M, Reinhardt S, Lobron C, Hermsen B, Maelicke A, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptor subunits by in situ hybridization. J Pharmacol Exp Ther 1994;271:494-506
78. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 1999;19:2693-705
79. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996;383:713-6
80. Zarei MM, Radcliffe KA, Chen D, Patrick JW, Dani JA. Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience 1999;88:755-64
81. Alkondon M, Pereira EF, Albuquerque EX. Mapping the location of functional nicotinic and gamma-aminobutyric acidA receptors on hippocampal neurons. J Pharmacol Exp Ther 1996;279:1491-506
82. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999;22:555-61
83. Mui WC, Zbuzek VK, Wu WH. GABA(A) antagonist and nicotine-induced antinociception. Life Sci 1997;61:221-5
84. Flores CM, Wilson SG, Mogil JS. Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception. Pharmacogenetics 1999;9:619-25
85. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux JP. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999;398:805-10
86. Levin ED, Rose JE. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Res Bull 1991;27:125-8
87. Levin ED. Nicotinic systems and cognitive function. Psychopharmacology (Berl) 1992;108(4):417-31
88. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997;48:649-84
89. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998;138:217-30
90. Adler LE, Freedman R, Ross RG, Olincy A, Waldo MC. Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry 1999;46:8-18
91. Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE. Transdermal nicotine effects on attention. Psychopharmacology (Berl) 1998;140:135-41
92. White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology (Berl) 1999;143:158-65
93. Bourin M, Ripoll N, Dailly E. Nicotinic receptors and Alzheimer's disease. Curr Med Res Opin 2003;19:1-9
94. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989;154:797-800
95. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992;108:485-94
96. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 1996;32:67-73
97. Levin ED, Conners CK, Sparrow E, Hinton S, Meck W, Rose JE, Ernhardt D, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1996c;123:55-63
98. Mirza NR, Stolerman IP. Nicotine enhances sustained attention in the rat under specific task conditions. Psychopharmacology (Berl) 1998;138:266-74
99. Grottick AJ, Higgins GA. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 2000;117:197-208
100. Stolerman IP, Mirza NR, Hahn B, Shoaib M. Nicotine in an animal model of attention. Eur J Pharmacol 2000;393:147-54
101. Hahn B, Stolerman IP. Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine. Neuropsychopharmacology 2002;27:712-22
102. Bontempi B, Whelan KT, Risbrough VB, Joppa MA, Kille N, Buccafusco JJ, Menzaghi F, Lloyd GK. SIB-1553A, a novel nAChR agonist with cognitive enhancing properties in aged rodents and non-human primates; effects on various memory forms. Soc Neurosci 1997, Abstr;23:477.15
103. Menzaghi F, Joppa MA, Reid RT, Sacaan AI, Bontempi B, Whelan KT, Santori EM, Risbrough VB, Lloyd GK. Memory deficits associated with cholinergic dysfunctions: reversal by SIB-1553A, a novel nAChR agonist. Soc Neurosci Abstr 1997;23:477.16
104. Grottick AJ, Wyler R, Higgins GA. A study of the nicotinic agonist SIB-1553A on locomotion and attention as measured by the five-choice serial reaction time task. Pharmacol Biochem Behav 2001;70:505-13
105. Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 1992;587:130-6
106. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996;22:431-45
107. Leonard S, Gault J, Adams C, Breese CR, Rollins Y, Adler LE, Olincy A, Freedman R. Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 1998b;12:195-201
108. Leonard S, Gault J, Moore T, Hopkins J, Robinson M, Olincy A, Adler LE, Cloninger CR, Kaufmann CA, Tsuang MT, Faraone SV, Malaspina D, Svrakic DM, Freedman R. Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. Am J Med Genet 1998c;81:308-12
109. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 1997;94:587-92
110. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166-74
111. Huerta PT, Lisman JE. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature, 1993;364:723-5
112. Levin ED, Rose JE, McGurk SR, Butcher LL. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav Neural Biol 1990;53:103-12
113. Levin ED, Rose JE. Acute and chronic nicotinic interactions with dopamine systems and working memory performance. Ann N Y Acad Sci 1995;757:245-52
114. Levin ED, Torry D. Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology (Berl) 1996;123:88-97
115. Warburton DM, Arnall C. Improvements in performance without nicotine withdrawal. Psychopharmacology (Berl) 1994;115:539-42
116. Warburton DM, Mancuso G. Evaluation of the information processing and mood effects of a transdermal nicotine patch. Psychopharmacology (Berl) 1998;135:305-10
117. Buccafusco JJ, Jackson WJ, Terry AV Jr, Marsh KC, Decker MW, Arneric SP. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 1995;120:256-66
118. Decker MW, Curzon P, Brioni JD, Arneric SP. Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. Eur J Pharmacol 1994;261:217-22
119. Meyer EM, de Fiebre CM, Hunter BE, Simpkins CE, Frauworth N, de Fiebre NE. Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev Res 1994;31:127-34
120. Levin ED, Christopher NC, Weaver T, Moore J, Brucato F. Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. Brain Res Cogn Brain Res 1999a;7:405-10
121. Levin E, Christopher N. Persistence of nicotinic agonist RJR 2403 induced working memory improvement in rats. Drug Dev Res 2002;55:97-103
122. Addy NA, Nakijama A, Levin ED. Nicotinic mechanisms of memory: effects of acute local DHbetaE and MLA infusions in the basolateral amygdala. Brain Res Cogn Brain Res 2003; 16:51-7
123. Gaddnas H, Pietila K, Alila-Johansson A, Ahtee L. Pineal melatonin and brain transmitter monoamines in CBA mice during chronic oral nicotine administration. Brain Res 2002;957:76-83
124. Goelet P, Castellucci VF, Schacher S, Kandel ER. The long and the short of long-term memory - a molecular framework. Nature 1986;322:419-22
125. Lein ES, Shatz CJ. Rapid regulation of brain-derived neurotrophic factor mRNA within eye-specific circuits during ocular dominance column formation. J Neurosci 2000;20:1470-83
126. Broide RS, Leslie FM. The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 1999;20:1-16
127. Janson AM, Fuxe K, Agnati LF, Jansson A, Bjelke B, Sundstrom E, Andersson K, Harfstrand A, Goldstein M, Owman C. Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat. Prog Brain Res 1989;79:257-65
128. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997;42:159-63
129. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997;11:206-28
130. Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 2000;113:21-34
131. Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial dimesencephalic hemitransection. Naunyn Schmiedebergs Arch Pharmacol, 1990;341:171-81
132. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J. 1999;18:1235-44
133. Shimohama S, Greenwald DL, Shafron DH, Akaika A, Maeda T, Kaneko S, Kimura J, Simpkins CE, Day AL, Meyer EM. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998;779:359-63
134. Li Y, Papke RL, He YJ, Millard WJ, Meyer EM. Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells. Brain Res 1999;830:218-25
135. Donnelly-Roberts DL, Xue IC, Arneric SP, Sullivan JP. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res 1996;719:36-44
136. Arnold S, Trojanowsky J. Recent advances in defining the neuropathology of schizophrenia. Acta Neuropathol 1996;92:217-31
137. Cannon TD. Abnormalities of brain structure and function in schizophrenia: implications for aetiology and pathophysiology. Ann Med 1996;28:533-9
138. Jones EG. Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997;23:483-501
139. Shapiro R. Regional Neuropathology in schizophrenia: Where are we? Where are we going? Schizophr Res 1993;10:187-239
140. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61
141. Jarrard LE. What does the hippocampus really do? Behav Brain Res 1995;71:1-10
142. Jones ED. The Thalamus. New York: Plenum Press, 1985
143. Crosson B, Hughes CW. Role of the thalamus in languagels it related to schizophrenic thought disorder. Schizophr Bull 1987;13:605-21
144. Ingvar D. Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: the phenomen of 'hypofrontaly' reconsidered. In: Helmchen H, Henn A. (Eds), Biological Perspectives of schizophrenia. Wiley: Chicester, 1987:201-11
145. Weinberger D. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9
146. Powers R. The neuropathology of schizophrenia. Neuropathol Exp Neurol 1999;58:679-90
147. Freedman R, Adams CE, Leonard S. The α7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanatomy 2000;20:299-306
148. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, Kerwin R, Perry R, Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999;73:1590-7
149. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995;38:22-33
150. Pomper MG, Webster M, Bobo LD. Hippocampal α7 nicotinic cholinergic receptor, neuronal nitric oxide synthase, and glutamic acid decarboxylase mRNA co-localization in schizophrenia. Schizophr Res 1999;36:75-85
151. Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic acetylcholine receptor 7 subunit in the frontal cortex from schizophrenic brain. NeuroReport 1999;10:1779-82
152. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002;77:501-5
153. Breese C, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, Marks MJ, Collins AC, Leonard S. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000;23:351-64
154. Agulhon C, Abitbol M, Bertrand D, Malafosse A. Localization of mRNA for CHRNA7 in human fetal brain. Neuroreport 1999;10:2223-7
155. Komuro H, Rakic P. Intracellular Ca2+ fluctuations modulate the rate of neuronal migration. Neuron 1996;17:275-85
156. Browning MD, Dudek EM, Rapier JL, Leonard S, Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol. Psychiatry 1993;34:529-35
157. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry 1996;39:82-91
158. Hellström-Lindahl E, Gorbounova O, Seiger A, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res Dev Brain Res 1998;108:147-60
159. Hunt S, Schmidt J. The relationship of alpha-bungarotoxin binding activity and cholinergic termination within the rat hippocampus. Neuroscience 1979;4:585-92
160. Fuchs JL. [125I]alpha-bungarotoxin binding marks primary sensory area developing rat neocortex. Brain Res 1989;501:223-34
161. Haroutunian V, Davidson M, Kanof PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL. Cortical cholinergic markers in schizophrenia. Schizophr Res 1994;12:137-44
162. Berger F, Gage FH, Vijayaraghavan S. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 1998;18:6871-81
163. Orr-Urtreger A, Broide RS, Kasten MR, Dani JA, Beaudet AL, Patrick JW. Mice homozygous for the L250T mutation in the α7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within one day of birth. J Neurochem 2000;74:2154-66
164. Orr-Urtreger A, Broide RS, Kasten MR, Dang H, Dani JA, Beaudet AL, Patrick JW. Mice homozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. J Neurochem 2000;74:2154-66
165. Woo TU, Miller JL, Lewis DA. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 1997;154:1013-5
166. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Nat Acad Sci USA 1998;95:5341-6
167. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen Psychiatry 1995;52:805-18
168. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol 1998;392:402-12
169. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol Psychiatry 1999;4:39-45
170. Durany N, Zöchling R, Boissl K, Paulus W, Ransmayr G, Tatscher T, Danielczyk W, Jellinger K, Deckert J, Riederer P. Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000;287:109-12
171. Freedman R. Biological phenotypes in the genetics of schizophrenia. Biol Psychiatry 1998;44:939-40
172. Lee MJ, Breese CR, Strook ML, Leonard S. The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain. Mol Brain Res 2001;86:115-24
173. Hall M, Zerbe L, Leonard S, Freedman R. Characterization of [3H]cytisine binding to human brain membrane preparations. Brain Res 1993;600:127-33
174. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull 1993;19:431-45
175. Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 1998;32:201-14
176. Benwell ME, Balfour DJ, Andreson JM. Evidence that tobacco smoking increases the density of (-)-[3H] nicotine binding sites in human postmortem brain. J Neurochem 1988;50:1243-7
177. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography. J Pharmac Exp Ther 1999;289:1545-52
178. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, Collins AC, Leonard S. Effect of smoking history on [3H] nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997a;282:7-13
179. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar K. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992;41:31-7
180. Gorell MM, Rybycki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease. A dose-response relationship. Neurology 1999;52:115-9
181. James JR, Nordberg A. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet 1995;25:149-59
182. Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 1994;46:523-30
183. Vibat CR, Lasalde JA, McNamee MG, Ochoa EL. Differential desensitization properties of rat neuronal nicotinic acetylcholine receptor subunit combinations expressed in Xenopus laevis oocytes. Cell Mol Neurobiol 1995;15:411-25
184. Baenziger JE, Chew JP. Desensitization of nicotinic acetylcholine receptor mainly involves a structural change in solvent-accessible regions of the polypeptide backbone. Biochemistry 1997;36:3617-24
185. Marks MJ, Pauly JR, Gross SD, Deneris ES, Hermans-Borgmeyer I, Heinemann SF, Collins AC. Nicotine binding and nicotinic receptor subunit mRNA after chronic nicotine treatment. J Neurosci 1992;12:2765-84
186. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992;32:607-16
187. Venables P. Input dysfunction in schizophrenia. In: Maher, B.A., ed. Progress in Experimental Personality Research. New York, NY: Academic Press, 1964:1-47
188. Perry W, Braff DL. Information-processing deficits and thought disorder in schizophrenia. Am J Psychiatry 1994;151:363-7
189. Radant AD, Claypoole K, Wingerson DK, Cowley DS, Roy-Byrne PP. Relationships between neuropsychological and oculomotor measures in schizophrenia patients and normal controls. Biol Psychiatry 1997;42:797-805
190. Filion DL, Dawson ME, Schell AM. The psychological significance of human startle eyeblink modification: a review. Biol Psychol 1998;47:1-43
191. Ross RG, Olincy A, Harris JG, Radant A, Adler LE, Freedman R. Anticipatory saccades during smooth pursuit eye movements and familial transmission of schizophrenia. Biol Psychiatry 1998b;44:690-7
192. Boutros NN, Zouridakis G, Overall J. Replication and extension of P50 findings in schizophrenia. Clinical Electroencephalography 1991;22:40-5
193. Erwin RJ, Mawhinney HM, Gur RC, Gur RE. Midlatency evoked responses in schizophrenia. Biol Psychiatry 1991;22:40-45
194. Judd LL, McAdams L, Budnick B, Braff DL. Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992;149:488-93
195. Hershman KM, Freedman R, Bickford PC. GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus. Neurosci Lett 1995;190:133-6
196. Davis H, Mast T, Yoshie N, Zerlin S. The slow response of the human cortex to auditory stimuli: recovery process. Electroencephalography and Clinical Neurophysiology 1966;21:105-13
197. Eccles JC. The inhibitory pathways of the central nervous system. Springfield, IL: Charles C Thomas Publisher, 1969
198. Grillon C, Ameli R, Braff DL. Middle latency auditory evoked potentials (MAEPs) in chronic schizophrenics. Schizophr Res 1991;5:61-6
199. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983;18:537-51
200. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry 1984;41:607-12
201. Baker N, Adler LE, Franks RD, Waldo M, Berry S, Nagamoto H, Muckle A, Freedman R. Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. Biol Psychiatry 1987;22:603-17
202. Adler L.E, Gerhardt G.A, Franks R, Baker N, Nagamoto H, Drebing C, Freedman R. Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res 1990;31:297-309
203. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT. Co-distribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 1991;39:257-68
204. Erwin RJ, Shtasel D, Gur RE. Effects of medication history on midlatency auditory evoked responses in schizophrenia. Schizophr Res 1994;11:251-8
205. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996;40:181-8
206. Baribeau-Braun J, Picton TW, Gosselin JY. Schizophrenia: a neurophysiological evaluation of abnormal information processing. Science 1983;219:874-6
207. Duncan CC. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr Bull 1988;14:199-203
208. Ford JM, Pfefferbaum A, Roth W. P3 and schizophrenia. Ann N.Y Acad Sci 1992;658:146-62
209. Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, Yilmaz A. Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:173-7
210. Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, Griffith JM, Harris JG, Leonard S, Miller C. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry 1994;2:179-92
211. Vijayaraghavan S, Pugh PC, Zhang ZW, Rathouz MM, Berg DK. Nicotinic receptors that bind alpha-bungarotoxin on neurons raise intracellular free Ca2+. Neurons 1992;8:353-62
212. Griffith J, Waldo M, Adler LE, Freedman R. Normalization of auditory sensory gating in schizophrenics after a brief period for sleep. Psychiatry Res 1993;49:29-39
213. Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry 1998;44:98-106
214. Griffith J, Freedman R. Normalization of the auditory P50 gating deficit of schizophrenic patients after NREM, but not REM sleep. Psychiatry Res 1995;56:271-8
215. Domino EF. Tobacco smoking and nicotine neuropsychopharmacology: some future research directions. Neuropsychopharmacology 1998;18:456-68
216. Karson CN, Casanova MF, Kleinman JE, Griffin WS. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993;150:454-9
217. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994;20:31-46
218. Katsanis J, Kortenkamp S, Iacono WG, Grove WM. Antisaccade performance in patients with schizophrenia and affective disorder. J Abnorm Psychol 1997;106:468-72
219. Holzman PS, Solomon CM, Levin S, Waternaux CS. Pursuit eye movement dysfunctions in schizophrenia. Family evidence for specificity. Arch Gen Psychiatry 1984;41:136-9
220. Holzman PS, Kringlen E, Matthysse S, Flanagan SD, Lipton RB, Cramer G, Levin S, Lange K, Levy DL. A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiatry 1988;45:641-7
221. Holzman PS, Matthysse S, Levy DL. Eye tracking dysfunction is associated with partial trisomy of chromosome 5 and schizophrenia: a response. Arch Gen Psychiatry 1989;46:756-8
222. Clementz BA, Sweeney JA. Is eye movement dysfunction a biological marker for schizophrenia? A methodological review. Psychol Bull 1990;108:77-92
223. Clementz BA, Grove WM, Iacono WG, Sweeney JA. Smooth-pursuit eye movement dysfunction and liability for schizophrenia: implications for genetic modeling. J Abnorm Psychol 1992;101:117-29
224. Ross RG, Olincy A, Harris JG, Radant A, Adler LE, Compagnon N. The effects of age on a smooth pursuit tracking task in adults with schizophrenia and normal subjects. Biol Psychiatry 1996;46:383-91
225. Thaker GK, Ross DE, Cassady SL, Adami HM, Medoff DR, Sherr JD. Saccadic eye movement abnormalities in relatives of patients with schizophrenia. Schizophrenia Res 2000;45:235-44
226. Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002;52:721-8
227. Eccles JC, Ito M, Szentagothai J. The cerebellum as neuronal machine. New York: Springer, 1967
228. O'Driscoll GA, Strakowski SM, Alpert NM, Matthysse SW, Rauch SL and Levy DL. Differences in cerebral activation during smooth pursuit and saccadic eye movements using positron-emission tomography. Biol Psychiatry 1998;44:685-9
229. Petit L, Orssaud C, Tzourio N, Salamon G, Mazoyer B, Berthoz A. PET study of voluntary saccadic eye movements in humans: Basal ganglia-thalamocortical system and cingulate cortex involvement. J Neurophysiol 1993;69:1009-17
230. Sweeney JA, Mintun MA, Kwee S, Wiseman MB, Brown DL, Rosenberg DR. Positron emission tomography study of voluntary saccadic eye movements and spatial working memory. J Neurophysiol 1996;75:454-68
231. Berman RA, Colby CL, Genovese CR, Voyvodic JT, Luna B, Thulborn KR. Cortical networks subserving pursuit and saccadic eye movements in humans: An FMRI study. Hum Brain Mapping 1999;8:209-25
232. Petit L, Haxby JV. Functional anatomy of pursuit eye movements in humans as revealed by fMRI. J Neurophysiol 1999;82:463-71
233. Van Gelder P, Lebedev S, Tsui WH. Predictive human pursuit and 'orbital goal' of microstimulated smooth eye movements. J Neurophysiol 1995;74:1358-61
234. Thaker GK, Ellsberry R, Moran M, Lahti A, Tamminga C. Tobacco smoking increases square-wave jerks during pursuit eye movements. Biol Psychiatry 1991;29:82-8
235. Ross RG, Harris JG, Olincy A, Radant A, Adler LE, Freedman R. Familial transmission of two independent saccadic abnormalities in schizophrenia. Schizophr Res 1998a;30:59-70
236. Dépatie L, O'Driscoll GA, Holahan ALV, Atkinson V, Thavundayil JX, Ng Ying Kin N, Lal S. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002;27:1056-70
237. Olincy A, Ross RG, Young DA, Roath M, Freedman R. Smooth eye pursuit eye movements after smoking in schizophrenic patients. [Abstract] Biological Psychiatry 1996;39:574
238. Olincy A, Ross RG, Young DA, Roath M, Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998;18:175-85
239. Klein C, Andresen B. On the influence of smoking upon pursuit eye movements of schizophrenics and normal controls. J Psychophysiol 1991;5:361-9
240. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002;27:479-97
241. Tootell RB, Reppas JB, Kwong KK, Malach R, Born RT, Brady TJ. Functional analysis of human MT and related visual cortical areas using magnetic resonance imaging. J Neurosci 1995;15:3215-30
242. Barnes GR, Barnes DM, Chakraborti SR. Ocular pursuit responses to repeated, single-cycle sinusoids reveal behavior compatible with predictive pursuit. J Neurophysio 2000;84:2340-55
243. Coull JT. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998;55:343-61
244. Straube A, Ditterich J, Oertel W, Kupsch A. Electrical stimulation of the posteroventral pallidum influences internally guided saccades in Parkinson's disease. J Neurol 1998;245:101-5
245. Hikosaka O, Wurtz RH. Visual and oculomotor functions of monkey substantia nigra pars reticulata. IV. Relation of substantia nigra to superior colliculus. J Neurophysiol 1983;49:1285-301
246. Hikosaka O, Sakamoto M, Usui S. Functional properties of monkey caudate neurons. I. Activities related to saccadic eye movements. J Neurophysiol 1989;4:780-98
247. Tian JR, Lynch JC. Subcortical input to the smooth and saccadic eye movement subregions of the frontal eye field in cebus monkey. J Neurosci 1997;17:9233-47
248. Kori A, Miyashita N, Kato M, Hikosaka O, Usui S, Matsumura M. Eye movements in monkeys with local dopamine depletion in the caudate nucleus. II. Deficits in voluntary saccades. J Neurosci 1995;15:928-41
249. MacAvoy MJ, Gottlieb JP, Bruce CJ. Smooth pursuit eye movement representation in the primate frontal eye field. Cereb Cortex 1991;1:92-102
250. O'Driscoll GA, Alpert NM, Matthysse SW, Levy DL, Rauch SR, Holzman PS. The functional neuroanatomy of antisaccade performance investigated with positron emission tomography. Proc Natl Acad Sci USA 1995;92:925-9
251. Kodaka Y, Mikami A, Kubota K. Neuronal activity in the frontal eye field of the monkey is modulated while attention is focused on to a stimulus in the peripheral visual field, irrespective of eye movement. Neurosci Res 1997;28:291-8
252. Ross DT, Graham DI. Selective loss and sparing of neurons in the thalamic reticular nucleus following human cardiac arrest. J Cereb Blood Flow Metab 1993;13:558-67
253. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, Kosten TR, Wexler BE. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85
254. Greeman M, McClellan TA. Negative effects of a smoking ban on an inpatient psychiatry service. Hosp Community Psychiatry 1991;42:408-12
255. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Nestadt G, Antonarakis S, Housman D, Kazazian HH, Meyers D. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am J Med Genet 1994;54:36-43
256. Straub RE, MacLean CJ, Kendler KS. The putative schizophrenia locus on chromosome 6p: a brief overview of the linkage studies. Mol Psychiatry 1996;1:89-92
257. Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A, Markey CJ, Beshah E, Guroff JJ, Maxwell ME, Kazuba DM, Whiten R, Goldin LR, Gershon ES, Gejman PV. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997;43:1-8
258. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, Thornquist M, Ullrich G, McGrath J, Kasch L, Lamacz M, Thomas MG, Gehrig C, Radhakrishna U, Snyder SE, Balk KG, Neufeld K, Swartz KL, DeMarchi N, Papadimitriou GN, Dikeos DG, Stefanis CN, Chakravarti A, Childs B, Pulver AE. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998;20:70-3
259. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, Hampe C, Zambuto CT, Schmitt K, Meyer J, Markel P, Lee H, Harkavy Friedman J, Kaufmann C, Cloninger CR, Tsuang MT. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet 1998;81:290-5
260. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000;288:678-82
261. Gejman PV, Sanders AR, Badner JA, Cao Q, Zhang J. Linkage analysis of schizophrenia to chromosome 15. Am J Med Genet 2001;105:789-93
262. Riley BP, Makoff A, Mogudi-Carter M, Jenkins T, Williamson R, Collier D, Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. Am J Med Genet 2000;96:196-201
263. Baron M. Genetics of schizophrenia and the new millennium: progress and pitfalls. Am J Hum Genet 2001;68:299-312
264. Freedman R, Adler LE, Baker N, Waldo M, Mizner G. Candidate for inherited neurobiological dysfunction in schizophrenia. Somat Cell Mol Genet 1987;13:479-84
265. Freedman R, Waldo M, Bickford-Wimer P, Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophr Res 1991;4:233-43
266. Holzman PS. Smooth pursuit eye movements in psychopathology. Schizophr Bull 1983;9:33-6
267. Waldo MC, Adler LE, Leonard S, Olincy A, Ross RG, Harris JG, Freedman R. Familial transmission of risk factors in the first-degree relatives of schizophrenic people. Biol Psychiatry 2000;47:231-9
268. Waldo M, Myles-Worsley M, Madison A, Byerley W, Freedman R. Sensory gating deficits in parents of schizophrenics. Am J Med Genet 1995;60:506-11
269. Coon H, Plaetke R, Holik J, Hoff M, Myles-Worsley M, Waldo M, Freedman R, Byerley W. Use of a neurophysiological trait in linkage analysis of schizophrenia. Biol Psychiatry 1993;34:277-89
270. Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics 1994;19:379-81
271. Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS, Read T, Murphy P, Blaveri E, McQuillin A, Petursson H, Curtis D. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am J Hum Genet 2001;68:661-73
272. Blaveri E, Kalsi G, Lawrence J, Quested D, Moorey H, Lamb G, Kohen D, Shiwach R, Chowdhury U, Curtis D, McQuillin A, Gramoustianou ES, Gurling HM. Genetic association studies of schizophrenia using the 8p21-22 genes: prepronociceptin (PNOC), neuronal nicotinic cholinergic receptor alpha polypeptide 2 (CHRNA2) and arylamine N-acetyltransferase 1 (NAT1). Eur J Hum Genet 2001;9:469-72
273. Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne D, Faraone SV, Tsuang MT, Cloninger CR. NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 1998;81:282-9
274. Stassen HH, Bridler R, Hagele S, Hergersberg M, Mehmann B, Schinzel A, Weisbrod M, Scharfetter C. Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet 2000;96:173-7
275. Stober G, Saar K, Ruschendorf F, Meyer J, Nurnberg G, Jatzke S, Franzek E, Reis A, Lesch KP, Wienker TF, Beckmann H. Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. Am J Hum Genet 2000;67:1201-7
276. Tsuang DW, Skol AD, Faraone SV, Bingham S, Young KA, Prabhudesai S, Haverstock SL, Mena F, Menon AS, Bisset D, Pepple J, Sauter F, Baldwin C, Weiss D, Collins J, Boehnke M, Schellenberg GD, Tsuang MT. Examination of genetic linkage of chromosome 15 to schizophrenia in a large Veterans Affairs Cooperative Study sample. Am J Med Genet 2001;105:662-8
277. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:1085-96
278. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, Tsuang MT, Farone SV, Malaspina D, Svrakic DM, Sanders A, Gejman P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001;105:20-2
279. Xu J, Pato MT, Torre CD, Medeiros H, Carvalho C, Basile VS, Bauer A, Dourado A, Valente J, Soares MJ, Macedo AA, Coelho I, Ferreira CP, Azevedo MH, Macciardi F, Kennedy JL, Pato CN. Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families. Am J Med Genet 2001;105:669-74
280. Meyer J, Ortega G, Schraut K, Nurnberg G, Ruschendorf F, Saar K, Mossner R, Wienker TF, Reis A, Stober G, Lesch KP. Exclusion of the neuronal nicotinic acetylcholine receptor alpha7 subunit gene as a candidate for catatonic schizophrenia in a large family supporting the chromosome 15q13-22 locus. Mol Psychiatry 2002;7:220-3
281. Lai IC, Hong CJ, Tsai SJ. Association study of a nicotinic receptor variant with schizophrenic disorders. Neuropsychobiology 2001;43:15-8
282. Raux G, Bonnet-Brilhault F, Louchart S, Houy E, Gantier R, Levillain D, Allio G, Haouzir S, Petit M, Martinez M, Frebourg T, Thibaut F, Campion D. The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol Psychiatry 2002;7:1006-11
283. Alkondon M, Pereira EF, Almeida LE, Randall WR, Albuquerque EX. Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus. Neuropharmacology 2000;39:2726-39
284. Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs 2002;62:1-9
285. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, Cooper TB: Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993;54:670-9
286. Covey L, Hughes DC, Glassman AH, Blazer DG, George LK. Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 1994;3:222-7
287. De Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996b;22:405-9
288. Addington J, el-Guebaly N, Addington D, Hodgins D. Readiness to stop smoking in schizophrenia. Can J Psychiatry 1997;42:49-52
289. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23:247-54
290. Allebeck P, Wistedt B. Mortality in schizophrenia. Arch Gen Psychiatry 1986;43:650-3
291. Tabbane K, Joober R, Spadone C, Poirier MF, Olié JP. Mortalité et causes de décès dans la schizophrénie: revue de la littérature. L'Encéphale 1993;19:23-8
292. Karson CN, Mrak RE, Husain MM, Griffin WS. Decreased mesopontine choline acetyltransferase levels in schizophrenia. Correlations with cognitive functions. Mol Chem Neuropathol 1996;29:181-91
293. Haroutunian V, Davidson M, Kanoff PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL. Cortical cholinergic markers in schizophrenia. Schizophr Res 1994;12:137-44
294. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002;51:349-57
295. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil study group. Neurology 1998;50:136-45
296. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001;49:279-88
297. Modestin J, Schwartz RB, Hunger J. [Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)] Pharmakopsychiatr Neuropsychopharmakol 1973;6:300-4
298. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23-49
299. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-8
300. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-76
301. Dale MC, Libretto SE, Patterson C, Anderson J, Choudhury T, McCafferty F, McWilliam C, Richardson M. Clinical experience of galantamine in dementia: a series of case reports. Curr Med Res Opin 2003;19:508-18
302. McEvoy JP, Allen TB, Keefe P, Levin E, Wilson W. The effects of galantamine in patients with refractory schizophrenia receiving risperidone. XIII World Congress of Psychiatry, Yokohama, Japan, 24-29 August 2002
303. Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 2002;159:1244-5